日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine

一项 1 期、多中心、开放标签研究,旨在评估单剂量瑞美吉泮在有偏头痛病史的儿童(年龄 ≥6 岁至 <12 岁)中的药代动力学、安全性和耐受性。

Lim, Chay Ngee; Mo, Gary; Bhardwaj, Rajinder; Comisar, Craig M; Emerson, Beth L; Matschke, Kyle T; Fisniku, Ogert; Bertz, Richard; Croop, Robert; Liu, Jing

A Pharmacokinetic Study of Zavegepant Nasal Spray in Healthy Adults Comparing Conventional Venous Blood Sampling With Patient-Centric Microsampling

一项针对健康成年人的Zavegepant鼻喷雾剂药代动力学研究:比较传统静脉血采样与以患者为中心的微量采样

Shahin, Mohamed H; Fisniku, Ogert; Ding, Ding; Wan, Katty; Dubrovin, Sergey; Matschke, Kyle; Kavetska, Olga; Fountaine, Robert; Liu, Jing

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate

乌帕替尼对敏感的细胞色素P450 2B6探针底物安非他酮药代动力学的影响特征分析

Mohamed, Mohamed-Eslam F; Minocha, Mukul; Trueman, Sheryl; Feng, Tian; Enejosa, Jeffrey; Fisniku, Ogert; Othman, Ahmed A

Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc

与 CCR5 辅助受体拮抗剂 vicriviroc 耐药性相关的人类免疫缺陷病毒 1 型 gp120 氨基酸突变的结构功能分析

Robert A Ogert, Lei Ba, Yan Hou, Catherine Buontempo, Ping Qiu, Jose Duca, Nicholas Murgolo, Peter Buontempo, Robert Ralston, John A Howe

Mutational analysis of the rous sarcoma virus DR posttranscriptional control element

劳斯肉瘤病毒DR转录后调控元件的突变分析

Ogert, R A; Beemon, K L